Amalgam Rx’s DoseCheck Receives SFDA Clearance in Saudi Arabia
Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, announced that our insulin titration solution, DoseCheck, will now help patients and their care teams manage their insulin and glucose in yet another country. We’re also proud to now be one of the only digital platform companies connecting healthcare providers, payers and life sciences companies on four continents!
About Amalgam Rx
Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies and health systems, Amalgam Rx has built an innovative platform for rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 7 billion RWE data points utilized by patients and providers on three continents. Amalgam is the manufacturer of the iSage Rx app and white-labeled variants, the first prescription-only mobile application for the automated titration of all brands of basal insulin to receive market authorization in the United States, EU, and Brazil. iSage Rx allows physicians to choose from multiple clinically validated basal insulin algorithms and to tailor the algorithms to the specific needs of their type 2 diabetes patients. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com.